We are direct about the limits of the evidence
If courts rule that adding B12 does not create meaningful clinical differentiation, many compounding pharmacies would need to stop producing semaglutide products entirely
doi: 10.3389/fphar.2026.1769333 Received 16 December 2025 Revised 09 April 2026 Accepted 20 April 2026 Published 21 May 2026 Volume 17 - 2026 Edited by Alasdair Barr, University of British Columbia, Canada Reviewed by Ze-Ka Chen, University of North Carolina at Chapel Hill, United States Judy Van Stralen, JPM van Stralen Medicine Professional Corporation, Canada Updates Copyright 2026 Young, Powell, Powell, Welling, Granata, Saal, Nash and Corliss
NAD is provided in a 10ml vial
MicroRNA: another pharmacological avenue for colorectal cancer
Who Should Consider IGF-1 LR3 IGF-1 LR3 is appropriate for: Experienced users already running a solid foundation (training, protein, sleep) People in an active recomposition phase wanting to accelerate lean muscle accrual Those already running or familiar with GH secretagogues who want to add direct IGF-1 receptor stimulation It's not appropriate for: Beginners who haven't first established a baseline with training and nutrition Anyone with active cancer history or elevated PSA (IGF-1 is mitogenic it drives cell growth, not selectively) People not monitoring blood glucose (hypoglycemia risk is real) Dosing Starting Dose 2030 mcg post-workout
